A combination of experimental approaches reveals a comprehensive picture of DOR pharmacology, which could help efforts towards better drug design.

Alleviate pain through research, education, and clinical practice. Discover how the Washington University Pain Center is dedicated to reducing human suffering.

The Department of Anesthesiology at WashU Medicine showcased its leadership in migraine research at the 2025 American Headache Society Meeting with multiple podium presentations, featured sessions, an...

Nageotte nodules, once overlooked, may hold the key to understanding and treating diabetic peripheral neuropathy.

YouTube video by National Institutes of Health (NIH)

Despite the prevalence of chronic pain, the approval of novel, non-opioid therapeutics has been slow. A major translational challenge in analgesic development is the difference in gene expression and ...

Individual researchers and university leaders need to make the case for science to their elected representatives and to the public at large.

Higginbotham et al. show that inflammatory pain increases opioid-evoked dopamine neuron activity to promote fentanyl use selectively in males. Ovarian hormones offer females protection, but estradiol’...

Mouse study points to an effective alternative to opioids

A peripherally restricted CB1 agonist (VIP36) targeting a cryptic receptor pocket was developed, showing high efficacy in mouse pain models with minimal side effects and tolerance, potentially revolut...

The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

Cryo-electron microscopy structures of native type A GABA receptors from human brain reveal diverse subunit compositions, protein binding partners and binding sites for antiepileptic drugs.

Select a state on the map to see the impact of NIH funding across America.

As many as two billion people suffer from it — including me. Can science finally bring us relief?